Pluristem Therapeutics to Present at the 2009 BIO International Convention as Part of the Israeli Delegation
Business Wire
Posted: 2009-05-05 08:01:00
Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that it has been invited to be one of twenty Israeli life science companies constituting the Israeli delegation to the 2009 BIO International Convention, to be held on May 18-21 in Atlanta. Mr. Zami Aberman, President and CEO, and Dr. William Prather, Sr. VP Corporate Development, will be available at the Israel Pavilion, Booth: 3747 on the Exhibition Floor, to address Pluristem’s upcoming clinical trial in the US, following FDA clearance, as well as the Company’s adult stem cell product pipeline.
“The life science industry in general and cell therapy in particular is an exciting field for scientists, physicians and investors,” stated Zami Aberman, Chairman, President and CEO of Pluristem. “The BIO International Convention is the perfect setting for the exchange of services, research ideas, and the discussion of innovative technologies.” |
